66 Views | 33 Downloads
Dean Follmann, Email: dfollmann@niaid.nih.gov
Conceptualization: D.F., M.M., and M.F. Methodology: D.F., M.F., and J.F. Formal Analysis: D.F., M.F., J.F., and A.M. Writing – original draft: D.F., M.C., M.O.B., and M.M. Writing – review & editing: D.F., J.F., M.P.F., D.M., A.M., H.M.E.S., H.J., N.D.-R., D.B., Y.F., M.M., M.P.O., G.A.H., A.H., K.-C.C., E.F.-N., K.C.T., F.I., L.R.B., J.M., H.Z., W.D., P.G.B., and M.S.C.
We thank the volunteers who participated in the COV-2069 and COVE clinical trials. We thank Heather Angier for assistance with technical editing. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. These studies were supported by the National Institutes of Health/National Institute of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
D.F., J.F., M.P.F., D.M., A.M., H.M.E.S., H.J., N.D.-R., D.B., Y.F., and M.M. have no competing interests to declare. M.P.O. is an employee, has stock options, a patent pending, and license and royalties with Regeneron Pharmaceuticals, Inc. G.A.H. is an employee and shareholder of Regeneron and is listed on pending patents for the REGEN-COV antibody cocktail. A.H. owns stock in Regeneron and Pfizer. K.-C.C. and E.F.-N. are employees and shareholders of Regeneron. K.C.T. and F.I. are employees and shareholders of Regeneron and are listed on a pending patent. L.R.B. is the Deputy Editor for the New England Journal of Medicine and has grants from the Bill and Melinda Gates Foundation, Harvard Medical School, the National Institutes of Health, and the Wellcome Trust. J.M. is an employee of and has stock options and stock grants from Moderna. H.Z. is an employee of and has stock options from Moderna. W.D. is an employee of Moderna. P.G.B. will be serving as an unpaid advisor on Moderna’s Zika Vaccine Advisory Board. M.S.C. serves on the scientific advisory boards of Aerium, ModexX, and Atea and has consulting roles with Astra Zenica and GSK.
Open Access funding provided by the National Institutes of Health (NIH).
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023